OK NICK .......
Ellipsis Biotherapeutics Corporation announced today that the company has restructured its research programs in order to focus on the clinical development of its lead compounds in Alzheimer's Disease. Personnel and resources have been realigned to expand the company's drug development capabilities and accelerate the development of this new program.
"Ellipsis is very excited about our new Neurologic Disease program. Based on our early discovery studies, the company's lead compounds may have potential use as therapeutic and preventative treatments for Alzheimer's Disease, as well as for several other neurological disorders," said Peter St George Hyslop, MD, Ellipsis' Chief Scientific Officer.
"In addition, because the compounds physically bind to the protein plaques that are the hallmark indicators of Alzheimer's Disease, Ellipsis is also pursuing their use as diagnostics for early disease detection and progression tracking."
Ellipsis' existing Inflammatory Bowel Disease program has reached a mature stage with validated therapeutic targets and diagnostic products available for partnering. The company is seeking additional funding for the new Neurological Disease Program.
"The increased focus and resources will place Ellipsis in a strong position to bring forward our most promising clinical candidates," said Laurence Rubin, MD, Ellipsis' Chief Executive Officer. "Our priority for the near term is to advance our lead compounds into clinical trials and to aggressively pursue their development in Alzheimer's Disease."
About Ellipsis: Ellipsis is a privately held drug discovery company with lead candidates in the diagnosis and treatment of Degenerative Neurologic Disorders, specifically Alzheimer's Disease. In addition, the company has discovery programs in Inflammatory Diseases, including Inflammatory Bowel Disease and Rheumatoid Arthritis. Ellipsis' central business strategy is to develop therapeutics and diagnostics through early clinical proof (Phase I/II of clinical trials) and partner downstream commercialization and marketing. With future projects, Ellipsis intends to retain the rights to identified compounds through later stages of the discovery and clinical trials process before seeking commercialization partners. Non-core discoveries as well as diagnostic applications in its core programs will be out-licensed.
GLTLongs --- GEO
AI
